Nov 11 (Reuters) - European Medicines Agency:
* EMA: COVID-19: EMA RECOMMENDS AUTHORISATION OF TWO
MONOCLONAL
ANTIBODY MEDICINES: 11/11/2021
* EMA’S HUMAN MEDICINES COMMITTEE (CHMP) HAS RECOMMENDED
AUTHORISING RONAPREVE (CASIRIVIMAB/IMDEVIMAB) AND REGKIRONA
(REGDANVIMAB) FOR COVID-19.
* EMA - CHMP RECOMMENDED AUTHORISING RONAPREVE FOR TREATING
COVID-19 IN ADULTS, ADOLESCENTS WHO DO NOT REQUIRE SUPPLEMENTAL
OXYGEN AND WHO ARE AT INCREASED RISK
* EMA - SAFETY PROFILE OF BOTH MEDICINES FAVOURABLE WITH A
SMALL
NUMBER OF INFUSION-RELATED REACTIONS
* EMA - CHMP CONCLUDED THAT BOTH MEDICINES’ BENEFITS ARE
GREATER
THAN THEIR RISKS FOR THEIR APPROVED USES
* EMA SAYS CHMP WILL NOW SEND ITS RECOMMENDATIONS FOR BOTH
MEDICINES TO EUROPEAN COMMISSION FOR RAPID LEGALLY BINDING
DECISIONS.
* EMA: RONAPREVE CAN ALSO BE USED FOR PREVENTING COVID-19 IN
PEOPLE AGED 12 YEARS AND OLDER WEIGHING AT LEAST 40 KILOGRAMS.
* EMA SAYS WITH REGARD TO REGKIRONA, COMMITTEE RECOMMENDED
AUTHORISING MEDICINE FOR TREATING ADULTS WITH COVID-19 WHO DO
NOT REQUIRE SUPPLEMENTAL OXYGEN
((Reuters.Briefs@thomsonreuters.com;))